Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

Abstract

Chemotherapy is not effective for hepatocellular carcinoma (HCC). HMG-CoA redutase inhibitors have cytostatic activity for cancer cells, but their clinical usefulness is unknown. To investigate whether pravastatin, a potent HMG-CoA reductase inhibitor, prolongs survival in patients with advanced HCC, this randomized controlled trial was conducted between February 1990 and February 1998 at Osaka University Hospital. 91 consecutive patients <71 years old (mean age 62) with unresectable HCC were enroled in this study. 8 patients were withdrawn because of progressive liver dysfunction; 83 patients were randomized to standard treatment with or without pravastatin. All patients underwent transcatheter arterial embolization (TAE) followed by oral 5-FU 200 mg(-1)d for 2 months. Patients were then randomly assigned to control (n = 42) and pravastatin (n = 41) groups. Pravastatin was administered at a daily dose of 40 mg. The effect of pravastatin on tumour growth was assessed by ultrasonography. Primary endpoint was death due to progression of HCC. The duration of pravastatin administration was 16.5 +/- 9.8 months (mean +/- SD). No patients in either group were lost to follow-up. Median survival was 18 months in the pravastatin group versus 9 months in controls (P = 0.006). The Cox proportional hazards model showed that pravastatin was a significant factor contributing to survival. Pravastatin prolonged the survival of patients with advanced HCC, suggesting its value for adjuvant treatment.

References 26

1. 1.

   Byington R. P., Jukema J. W., Salonen J. T., Pitt B., Bruschke A. V., Hoen H., Furberg C. D., Mancini G. B. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995;92(9):2419-2425.

   Not in our library10.1161/01.cir.92.9.2419

2. 2.

   Cavalli F., Rozencweig M., Renard J., Goldhirsch A., Hansen H. H. Phase II study of oral VP-16-213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol. 1981;17(10):1079-1082.

   Not in our library10.1016/0014-2964(81)90291-7

3. 3.

   Charnsangavej C., Chuang V. P., Wallace S., Soo C. S., Bowers T. Work in progress: transcatheter management of primary carcinoma of the liver. Radiology. 1983;147(1):51-55.

   Not in our library10.1148/radiology.147.1.6298860

4. 4.

   Choi T. K., Lee N. W., Wong J. Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer. 1984;53(3):401-405.

   Not in our library10.1002/1097-0142(19840201)53:3<401::aid-cncr2820530306>3.0.co;2-l

5. 5.

   Di Bisceglie A. M. Hepatitis C and hepatocellular carcinoma. Semin Liver Dis. 1995;15(1):64-69.

   Not in our library10.1055/s-2007-1007263

6. 6.

   El-Serag H. B., Mason A. C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745-750.

   Not in our library10.1056/nejm199903113401001

7. 7.

   Falkson G., MacIntyre J. M., Moertel C. G., Johnson L. A., Scherman R. C. Primary liver cancer. An Eastern Cooperative Oncology Group Trial. Cancer. 1984;54(6):970-977.

   Not in our library10.1002/1097-0142(19840915)54:6<970::aid-cncr2820540604>3.0.co;2-7

8. 8.

   Gibbs J. B., Pompliano D. L., Mosser S. D., Rands E., Lingham R. B., Singh S. B., Scolnick E. M., Kohl N. E., Oliff A. Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. J Biol Chem. 1993;268(11):7617-7620.

   Not in our library

9. 9.

   Goldstein J. L., Brown M. S. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425-430.

   Not in our library10.1038/343425a0

10. 10.

    Goldstein J. L., Helgeson J. A., Brown M. S. Inhibition of cholesterol synthesis with compactin renders growth of cultured cells dependent on the low density lipoprotein receptor. J Biol Chem. 1979;254(12):5403-5409.

    Not in our library

11. 11.

    Habenicht A. J., Glomset J. A., Ross R. Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J Biol Chem. 1980;255(11):5134-5140.

    Not in our library

12. 12.

    James G. L., Goldstein J. L., Brown M. S., Rawson T. E., Somers T. C., McDowell R. S., Crowley C. W., Lucas B. K., Levinson A. D., Marsters J. C. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science. 1993;260(5116):1937-1942.

    Not in our library10.1126/science.8316834

13. 13.

    Kandutsch A. A., Chen H. W. Consequences of blocked sterol synthesis in cultured cells. DNA synthesis and membrane composition. J Biol Chem. 1977;252(2):409-415.

    Not in our library

14. 14.

    Kawata S., Takaishi K., Nagase T., Ito N., Matsuda Y., Tamura S., Matsuzawa Y., Tarui S. Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis. Cancer Res. 1990;50(11):3270-3273.

    Not in our library

15. 15.

    Kohl N. E., Mosser S. D., deSolms S. J., Giuliani E. A., Pompliano D. L., Graham S. L., Smith R. L., Scolnick E. M., Oliff A., Gibbs J. B. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science. 1993;260(5116):1934-1937.

    Not in our library10.1126/science.8316833

16. 16.

    Maltese W. A., Defendini R., Green R. A., Sheridan K. M., Donley D. K. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Clin Invest. 1985;76(5):1748-1754.

    Not in our library10.1172/jci112165

17. 17.

    Matsuda Y., Kawata S., Nagase T., Maeda Y., Yamasaki E., Kiso S., Ishiguro H., Matsuzawa Y. Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Effects of serine protease inhibitor. Cancer. 1994;73(1):53-57.

    Not in our library10.1002/1097-0142(19940101)73:1<53::aid-cncr2820730111>3.0.co;2-w

18. 18.

    Okuda K., Fujimoto I., Hanai A., Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res. 1987;47(18):4967-4972.

    Not in our library

19. 19.

    Okuda K. Hepatocellular carcinoma: recent progress. Hepatology. 1992;15(5):948-963.

    Not in our library10.1002/hep.1840150532

20. 20.

    Sebolt-Leopold J. S., Dudley D. T., Herrera R., Van Becelaere K., Wiland A., Gowan R. C., Tecle H., Barrett S. D., Bridges A., Przybranowski S. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 1999;5(7):810-816.

    Not in our library10.1038/10533

21. 21.

    Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301-1307.

    Not in our library10.1056/nejm199511163332001

22. 22.

    Simonetti R. G., Cammà C., Fiorello F., Politi F., D'Amico G., Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci. 1991;36(7):962-972.

    Not in our library10.1007/bf01297149

23. 23.

    Sinensky M., Beck L. A., Leonard S., Evans R. Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem. 1990;265(32):19937-19941.

    Not in our library

24. 24.

    Stefanini G. F., Amorati P., Biselli M., Mucci F., Celi A., Arienti V., Roversi R., Rossi C., Re G., Gasbarrini G. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer. 1995;75(10):2427-2434.

    Not in our library10.1002/1097-0142(19950515)75:10<2427::aid-cncr2820751007>3.0.co;2-j

25. 25.

    Tsujita Y., Kuroda M., Shimada Y., Tanzawa K., Arai M., Kaneko I., Tanaka M., Masuda H., Tarumi C., Watanabe Y. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta. 1986;877(1):50-60.

    Not in our library10.1016/0005-2760(86)90117-7

26. 26.

    Yamada R., Sato M., Kawabata M., Nakatsuka H., Nakamura K., Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983;148(2):397-401.

    Not in our library10.1148/radiology.148.2.6306721

Cited by papers we hold 4

• Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer · 2022
  No notice
• Statins: a repurposed drug to fight cancer · 2021
  No notice
• Statin drugs to reduce breast cancer recurrence and mortality · 2018
  No notice
• Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance · 2010
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.